Trial | Treatment arms | PSA response* | Tumor response | ||||
---|---|---|---|---|---|---|---|
 |  | N | Response rate %, unless otherwise specified | Statistical comparison | N | Objective response rate % | Statistical comparison |
Carducci, 2004 [85] | Atrasentan | 408 | "smaller mean ↑ with atrasentan vs. placebo" | p = 0.025 | NR | ||
 | placebo | 401 |  |  |  |  |  |
Carducci, 2003 [79] | atrasentan 10 mg | median time-to-PSA progression: | Â | NR | |||
 |  | 89 | 5.5 mo | p = 0.002 |  |  |  |
 | atrasentan 2.5 mg | 95 | 5 mo | p = 0.055 |  |  |  |
 | placebo | 104 | 2.5 mo | NA |  |  |  |
Small, 2003 [86] | APC8015 | 82 | 4.9 | NR | NR | ||
 | placebo | 45 | 0 |  |  |  |  |
Small, 2002 [81] | suramin (3.192 g/m2) | 128 | 24 | p = 0.08 (test for trend) | 128 | 9 | p = 0.104 (test for trend) |
 | suramin (5.320 g/m2) | 124 | 28 |  | 124 | 7 |  |
 | suramin (7.661 g/m2) | 120 | 34 |  | 120 | 15 |  |
Ahmann, 2001 [87] | prinomastat (5 mg) mitoxantrone prednisone | 134 | 17†| p = NS | NR | ||
 | prinomastat (10 mg) mitoxantrone prednisone | 134 | 18†|  |  |  |  |
 | mitoxantrone prednisone placebo | 138 | 14†|  |  |  |  |
Small, 2000 [82] | suramin hydrocortisone | 228 | 33 | p = 0.01 | 76 | 4 (PR) | NR |
 | placebo hydrocortisone | 230 | 16 |  | 80 | 0 |  |
Debruyne, 1998 [83] | liarozole | 160 | 20 | p < 0.001 | NR | ||
 | CPA | 161 | 4 |  |  |  |  |